NEW YORK (GenomeWeb) – Akesogen and Targos Molecular Pathology today announced a partnership to offer traditional pathology and molecular biomarker services to the pharmaceutical and biotechnology industry.
As part of the deal the partners will offer immunohistochemistry, fluorescent in situ hybridization, and molecular and cytogenomic options. Akesogen is providing its 14,000-square-foot facility and genetic and molecular expertise to support Targo's capabilities in companion diagnostics, pathology, and biomarkers. In a statement, Akesogen CEO Robert Boisjoli said the deal gives his firm "a footprint to operate [outside] of the US."
Targos is based in Kassel, Germany and provides clinical biomarker services. Norcross, Ga.-based Akesogen provides biorepository services and high-throughput biomarker profiling and genomics analysis services.
Financial and other terms of the agreement were not disclosed.